Please login to the form below

Not currently logged in
Email:
Password:

GSK collaborates with SuperGen

GSK has entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets with SuperGen

GlaxoSmithKline (GSK) has entered into a multi-year collaboration to discover and develop cancer therapeutics based on epigenetic targets with SuperGen, a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signalling modulation. 

Under the terms of the agreement, SuperGen will progress candidate compounds through to early clinical proof of concept, after which GSK will have the right to exercise an option to develop further and commercialise resulting production on a global basis.

SuperGen will receive $5m upfront, inclusive of a $3m common stock investment, priced at a premium to market. Total potential development and commercialisation milestones payable to SuperGen could exceed $375m. This is in addition to the potential for tiered royalties payable on net sales of any products.
 

26th October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

blood
‘How is your day?’
The initiative that shows how plasma protein therapies improve lives...
women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....

Infographics